TW201625574A - 含有甲氧基黃酮之NOX抑制劑及NFκB抑制劑 - Google Patents
含有甲氧基黃酮之NOX抑制劑及NFκB抑制劑 Download PDFInfo
- Publication number
- TW201625574A TW201625574A TW104114409A TW104114409A TW201625574A TW 201625574 A TW201625574 A TW 201625574A TW 104114409 A TW104114409 A TW 104114409A TW 104114409 A TW104114409 A TW 104114409A TW 201625574 A TW201625574 A TW 201625574A
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- methoxylated
- nox
- hydroxy
- disease
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 26
- ZAIANDVQAMEDFL-UHFFFAOYSA-N 3-methoxy-2-phenylchromen-4-one Chemical compound O1C2=CC=CC=C2C(=O)C(OC)=C1C1=CC=CC=C1 ZAIANDVQAMEDFL-UHFFFAOYSA-N 0.000 title claims abstract description 15
- YEHDMSUNJUONMW-UHFFFAOYSA-N methoxyflavone Natural products COC1=CC=CC=C1C1=CC(=O)C2=CC=CC=C2O1 YEHDMSUNJUONMW-UHFFFAOYSA-N 0.000 title claims abstract description 11
- 201000010099 disease Diseases 0.000 claims abstract description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 37
- 239000003814 drug Substances 0.000 claims abstract description 32
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 claims abstract description 30
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 claims abstract description 30
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 28
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 26
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 claims abstract description 18
- FAWLNURBQMTKEB-URDPEVQOSA-N 213546-53-3 Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(O)=O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)N)C(C)C FAWLNURBQMTKEB-URDPEVQOSA-N 0.000 claims abstract description 16
- 229930003935 flavonoid Natural products 0.000 claims description 74
- 235000017173 flavonoids Nutrition 0.000 claims description 74
- 229930003944 flavone Natural products 0.000 claims description 55
- 150000002213 flavones Chemical class 0.000 claims description 55
- 235000011949 flavones Nutrition 0.000 claims description 55
- 150000002215 flavonoids Chemical class 0.000 claims description 52
- ZGHORMOOTZTQFL-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)chromen-4-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=CC=CC=C2O1 ZGHORMOOTZTQFL-UHFFFAOYSA-N 0.000 claims description 26
- -1 methoxy flavonoid Chemical class 0.000 claims description 26
- CLXVBVLQKLQNRQ-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5,7-dimethoxychromen-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 CLXVBVLQKLQNRQ-UHFFFAOYSA-N 0.000 claims description 16
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 15
- YZWIIEJLESXODL-UHFFFAOYSA-N 3,5,7-trimethoxy-2-(4-methoxyphenyl)chromen-4-one Chemical compound C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C=C(OC)C=C2O1 YZWIIEJLESXODL-UHFFFAOYSA-N 0.000 claims description 14
- ZXJJBDHPUHUUHD-UHFFFAOYSA-N 4',5,7-Trimethoxyflavone Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(OC)C=C(OC)C=C2O1 ZXJJBDHPUHUUHD-UHFFFAOYSA-N 0.000 claims description 14
- JRFZSUMZAUHNSL-UHFFFAOYSA-N chrysin 5,7-dimethyl ether Chemical compound C=1C(OC)=CC(OC)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 JRFZSUMZAUHNSL-UHFFFAOYSA-N 0.000 claims description 14
- WSQWAMGRHJQANC-UHFFFAOYSA-N 5-hydroxy-3,7-dimethoxy-2-(4-methoxyphenyl)chromen-4-one Chemical compound C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(O)C=C(OC)C=C2O1 WSQWAMGRHJQANC-UHFFFAOYSA-N 0.000 claims description 12
- OYCOUDKDRFJOCP-UHFFFAOYSA-N 5-hydroxy-3,7-dimethoxy-2-phenylchromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=CC=C1 OYCOUDKDRFJOCP-UHFFFAOYSA-N 0.000 claims description 12
- CBTHKWVPSIGKMI-UHFFFAOYSA-N galangin 3,5,7-trimethyl ether Chemical compound C=1C(OC)=CC(OC)=C(C(C=2OC)=O)C=1OC=2C1=CC=CC=C1 CBTHKWVPSIGKMI-UHFFFAOYSA-N 0.000 claims description 12
- IRZVHDLBAYNPCT-UHFFFAOYSA-N tectochrysin Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 IRZVHDLBAYNPCT-UHFFFAOYSA-N 0.000 claims description 12
- 230000032683 aging Effects 0.000 claims description 9
- ALGDHWVALRSLBT-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-3,5,7-trimethoxychromen-4-one Chemical compound C=1C(OC)=CC(OC)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 ALGDHWVALRSLBT-UHFFFAOYSA-N 0.000 claims description 8
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 8
- 206010012289 Dementia Diseases 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- IAFBOKYTDSDNHV-UHFFFAOYSA-N (2S)-(-)-5,7-dimethoxyflavanone Natural products O1C2=CC(OC)=CC(OC)=C2C(=O)CC1C1=CC=CC=C1 IAFBOKYTDSDNHV-UHFFFAOYSA-N 0.000 claims description 7
- HHGPYJLEJGNWJA-UHFFFAOYSA-N 5-hydroxy-3,3',4',7-tetramethoxyflavone Chemical compound C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HHGPYJLEJGNWJA-UHFFFAOYSA-N 0.000 claims description 7
- GXAPLLMJHZBIPX-UHFFFAOYSA-N Retusine Natural products O1C(=O)C(C)C(C)C(C)(O)C(=O)OCC2CCN3C2C1CC3 GXAPLLMJHZBIPX-UHFFFAOYSA-N 0.000 claims description 7
- 230000002757 inflammatory effect Effects 0.000 claims description 7
- KQNCAPDRHYRSCV-UHFFFAOYSA-N 3,5,7-trimethoxyflavone Natural products COC1=C(OC2=CC(=C(C=C2C1=O)OC)OC)C1=CC=CC=C1 KQNCAPDRHYRSCV-UHFFFAOYSA-N 0.000 claims description 6
- MJWUIOHNTXYHBI-UHFFFAOYSA-N 3,7-dimethylgalangin Natural products COC1=C(C(=O)c2cc(OC)cc(O)c2C1=O)c3ccccc3 MJWUIOHNTXYHBI-UHFFFAOYSA-N 0.000 claims description 6
- 206010009887 colitis Diseases 0.000 claims description 6
- 210000003205 muscle Anatomy 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- CKEXCBVNKRHAMX-UHFFFAOYSA-N (-)-naringenin 4',7-dimethyl ether Natural products C1=CC(OC)=CC=C1C1OC2=CC(OC)=CC(O)=C2C(=O)C1 CKEXCBVNKRHAMX-UHFFFAOYSA-N 0.000 claims description 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 5
- 208000002177 Cataract Diseases 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 208000027932 Collagen disease Diseases 0.000 claims description 5
- 206010012442 Dermatitis contact Diseases 0.000 claims description 5
- 208000002249 Diabetes Complications Diseases 0.000 claims description 5
- 206010012655 Diabetic complications Diseases 0.000 claims description 5
- 206010014561 Emphysema Diseases 0.000 claims description 5
- 208000001034 Frostbite Diseases 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 208000034486 Multi-organ failure Diseases 0.000 claims description 5
- 208000010718 Multiple Organ Failure Diseases 0.000 claims description 5
- 206010030113 Oedema Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 208000008469 Peptic Ulcer Diseases 0.000 claims description 5
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 5
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
- 206010047115 Vasculitis Diseases 0.000 claims description 5
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 5
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 5
- 208000026935 allergic disease Diseases 0.000 claims description 5
- LZERJKGWTQYMBB-UHFFFAOYSA-N apigenin 7,4'-dimethyl ether Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(OC)C=C2O1 LZERJKGWTQYMBB-UHFFFAOYSA-N 0.000 claims description 5
- 206010008118 cerebral infarction Diseases 0.000 claims description 5
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 208000010247 contact dermatitis Diseases 0.000 claims description 5
- 230000006378 damage Effects 0.000 claims description 5
- 206010015037 epilepsy Diseases 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 230000004065 mitochondrial dysfunction Effects 0.000 claims description 5
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 208000011906 peptic ulcer disease Diseases 0.000 claims description 5
- 208000001076 sarcopenia Diseases 0.000 claims description 5
- 230000035939 shock Effects 0.000 claims description 5
- 208000020431 spinal cord injury Diseases 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000008035 Back Pain Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 208000030507 AIDS Diseases 0.000 claims description 3
- 208000006820 Arthralgia Diseases 0.000 claims description 3
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 claims description 3
- 208000008930 Low Back Pain Diseases 0.000 claims description 3
- 208000003076 Osteolysis Diseases 0.000 claims description 3
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 3
- 206010051246 Photodermatosis Diseases 0.000 claims description 3
- 241000097929 Porphyria Species 0.000 claims description 3
- 208000010642 Porphyrias Diseases 0.000 claims description 3
- 208000008765 Sciatica Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 208000008445 altitude sickness Diseases 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 208000007565 gingivitis Diseases 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 208000029791 lytic metastatic bone lesion Diseases 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 230000008845 photoaging Effects 0.000 claims description 3
- 230000036262 stenosis Effects 0.000 claims description 3
- 208000037804 stenosis Diseases 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 206010028570 Myelopathy Diseases 0.000 claims description 2
- 208000004550 Postoperative Pain Diseases 0.000 claims description 2
- 230000009759 skin aging Effects 0.000 claims description 2
- ULSUXBXHSYSGDT-UHFFFAOYSA-N tangeretin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 ULSUXBXHSYSGDT-UHFFFAOYSA-N 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- IFHXSMSQHPVVSF-UHFFFAOYSA-N 3-hydroxy-7-methoxy-2-(4-methoxyphenyl)chromen-4-one Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=CC=C(OC)C=C2O1 IFHXSMSQHPVVSF-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 22
- 239000000284 extract Substances 0.000 description 87
- 108010002998 NADPH Oxidases Proteins 0.000 description 73
- 102000004722 NADPH Oxidases Human genes 0.000 description 73
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 62
- 239000003921 oil Substances 0.000 description 54
- 235000019198 oils Nutrition 0.000 description 53
- 235000006886 Zingiber officinale Nutrition 0.000 description 51
- 235000008397 ginger Nutrition 0.000 description 51
- 241000234314 Zingiber Species 0.000 description 50
- 239000000203 mixture Substances 0.000 description 43
- 238000000605 extraction Methods 0.000 description 41
- 239000003925 fat Substances 0.000 description 40
- 230000002401 inhibitory effect Effects 0.000 description 33
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 31
- 239000000243 solution Substances 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 28
- 239000002904 solvent Substances 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 238000000034 method Methods 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 14
- 241000196324 Embryophyta Species 0.000 description 13
- 238000010992 reflux Methods 0.000 description 13
- 238000002835 absorbance Methods 0.000 description 12
- 235000013305 food Nutrition 0.000 description 10
- 230000003078 antioxidant effect Effects 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 230000002265 prevention Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000010649 ginger oil Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000002158 endotoxin Substances 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 150000004667 medium chain fatty acids Chemical class 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 230000003449 preventive effect Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 239000000469 ethanolic extract Substances 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 239000004006 olive oil Substances 0.000 description 5
- 235000008390 olive oil Nutrition 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000395050 Kaempferia parviflora Species 0.000 description 4
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 4
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 4
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 241000234299 Zingiberaceae Species 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 210000004671 cell-free system Anatomy 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 235000012149 noodles Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 3
- 206010033645 Pancreatitis Diseases 0.000 description 3
- 239000012496 blank sample Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000004519 grease Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- HZSOKHVVANONPV-UHFFFAOYSA-N 2-(3-benzyltriazolo[4,5-d]pyrimidin-7-yl)sulfanyl-1,3-benzoxazole Chemical compound N1=NC2=C(SC=3OC4=CC=CC=C4N=3)N=CN=C2N1CC1=CC=CC=C1 HZSOKHVVANONPV-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 240000008415 Lactuca sativa Species 0.000 description 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000973887 Takayama Species 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 229940002508 ginger extract Drugs 0.000 description 2
- 235000020708 ginger extract Nutrition 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 150000004032 porphyrins Chemical class 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 235000012045 salad Nutrition 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- WHLQVYWQNZFUPW-UHFFFAOYSA-N 3-hydroxy-5-methoxy-2-phenylchromen-4-one Chemical compound OC=1C(=O)C=2C(OC)=CC=CC=2OC=1C1=CC=CC=C1 WHLQVYWQNZFUPW-UHFFFAOYSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 101100313763 Arabidopsis thaliana TIM22-2 gene Proteins 0.000 description 1
- 108700012434 CCL3 Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000000013 Chemokine CCL3 Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 244000008991 Curcuma longa Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 101001112221 Dictyostelium discoideum NADPH oxidase activator Proteins 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 244000062245 Hedychium flavescens Species 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 244000208060 Lawsonia inermis Species 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 208000029033 Spinal Cord disease Diseases 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 230000002019 anti-mutation Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 208000029771 childhood onset asthma Diseases 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000014058 juice drink Nutrition 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 231100001028 renal lesion Toxicity 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/304—Foods, ingredients or supplements having a functional effect on health having a modulation effect on allergy and risk of allergy
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
Abstract
本發明之課題為提供具有優良作用之NOX抑制劑及NFκB抑制劑、及利用其之起因於NOX或NFκB之疾病的預防或治療劑。因此,係使用特定之甲氧基黃酮。
Description
本發明係關於含有特定的甲氧基黃酮之NOX抑制劑及NFκB抑制劑、及其利用。
NADPH氧化酶(NOX)係存在於嗜中性球等,已知為生成O2-之酵素。因此,NOX之抑制,可認為係有用於生體內氧化所相關的各種疾病之預防或治療。
NFκB,係調節編碼發炎促進性細胞激素(例如TNFα、IL-1β、IL-6)、趨化激素(例如IL-8、MIP1α)、誘導性反應物酵素(effector enzyme)(iNOS及COX-2)等分子之基因轉錄的轉錄因子,其於發炎反應中擔當重要的角色。NFκB路徑的活化,顯示可造成各種之發炎性疾病。
植物之萃取物中所含之甲氧基黃酮,被報導其數種係具有抗氧化作用。如此之甲氧基黃酮多數具有羥基(非專利文獻1~3)。
黑薑(Kaempferia parviflora)係屬於薑科之植物的一種,日本亦稱為黑薑黃。黑薑於泰國係亦被稱作Kra chai dahm之傳統藥草之一種。已知黑薑中不僅含有
具有羥基之甲氧基黃酮,亦含有不具有羥基之甲氧基黃酮(非專利文獻4)。
[非專利文獻1] Biochem Pharamacol., 2012, 84(2), 182-191
[非專利文獻2] Free Radic Biol Med., 1999, 27(1-2), 95-99
[非專利文獻3] Biochem Pharmacol., 1987, 36(5), 717-720
[非專利文獻4] 大阪市立大學生活科學研究科 東銳明氏博士論文「薑科植物Kaempferia parviflora中所含的成分之構造與α-葡萄糖苷酶抑制活性及抗突變性」
本發明之課題係提供具有優良作用之NOX抑制劑及NFκB抑制劑、及起因於NOX或NFκB之疾病的預防或治療劑。
本發明者針對該課題努力探討的結果,發現由黑薑所得到之特定之甲氧基黃酮,具有優良的NOX抑
制作用及/或NFκB抑制作用。
亦即,本發明係關於以下者,但不限定於此等。
[1]一種NOX抑制劑,其係含有具有以下之式(I)
(式中,R1、R4、及R5,各自獨立地為氫或甲氧基,R2及R3為甲氧基)表示之構造的至少1種甲氧基黃酮。
[2]如[1]之NOX抑制劑,其中前述至少1種甲氧基黃酮,係選自由5,7,3’,4’-四甲氧基黃酮、3,5,7,3’,4’-五甲氧基黃酮、5,7-二甲氧基黃酮、及5,7,4’-三甲氧基黃酮所成之群A中。
[3]如[2]之NOX抑制劑,其中相對於群A之甲氧基黃酮;與由3,5,7-三甲氧基黃酮、3,5,7,4’-四甲氧基黃酮、5-羥基-3,7,3’,4’-四甲氧基黃酮、5-羥基-7-甲氧基黃酮、
5-羥基-7,4’-二甲氧基黃酮、5-羥基-3,7-二甲氧基黃酮、及5-羥基-3,7,4’-三甲氧基黃酮所成之群B之甲氧基黃酮的總含量而言,群A之甲氧基黃酮之總含量的比例(A/(A+B)),以莫耳基準計係超過0.65。
[4]一種起因於NOX之疾病的預防或治療劑,其係含有如前述[1]或[2]記載之至少1種甲氧基黃酮。
[5]如[4]之預防或治療劑,其中前述疾病係選自由過敏疾病、巴金森症、腦梗塞、白內障、癲癇、脊髓損傷、動脈硬化、早產兒視網膜病變、腎病變、消化性潰瘍、胰臟炎、潰瘍性大腸炎、心肌梗塞、成人呼吸窘迫症候群、肺氣腫、慢性類風濕性關節炎等之膠原病、血管炎、浮腫、糖尿病併發症、紫外線損害、高山症、卟啉血症、燒燙傷、凍傷、接觸性皮膚炎、休克、多重器官衰竭、DIC、癌、老化、疲勞、肌肉減少症(sarcopenia)(肌力低下)、粒線體功能失調、失智症、及阿茲海默症所成之群中。
[6]如[4]或[5]之預防或治療劑,其中相對於如前述[2]記載之群A之甲氧基黃酮、與如[3]記載之群B之甲氧基黃酮的總含量而言,群A之甲氧基黃酮之總含量的比例(A/(A+B)),以莫耳基準計係超過0.65。
[7]一種NFκB抑制劑,其係含有具有以下之式(I)
(式中,R1、R4、及R5,各自獨立地為氫或甲
氧基,R2及R3為甲氧基)表示之構造的至少1種甲氧基黃酮。
[8]如[7]之NFκB抑制劑,其中前述至少1種甲氧基黃酮,係選自由5,7,3’,4’-四甲氧基黃酮、5,7-二甲氧基黃酮、及5,7,4’-三甲氧基黃酮所成之群A’中。
[9]如[8]之NFκB抑制劑,其中相對於群A’之甲氧基黃酮;與由3,5,7,3’,4’-五甲氧基黃酮、3,5,7-三甲氧基黃酮、3,5,7,4’-四甲氧基黃酮、5-羥基-3,7,3’,4’-四甲氧基黃酮、5-羥基-7-甲氧基黃酮、5-羥基-7,4’-二甲氧基黃酮、5-羥基-3,7-二甲氧基黃酮、及5-羥基-3,7,4’-三甲氧基黃酮所成之群B’之甲氧基黃酮的總含量而言,群A’之甲氧基黃酮之總含量的比例(A’/(A’+B’)),以莫耳基準計係超過0.48。
[10]一種起因於NFκB之疾病的預防或治療劑,其係含有如前述[7]或[8]記載之至少1種甲氧基黃酮。
[11]如[10]之預防或治療劑,其中前述疾病係選自由
類風濕性關節炎、發炎性大腸炎、變形性關節症、骨溶解症、腱炎、坐骨神經痛、椎間盤突出、狹窄症、脊髓症、腰痛、椎間關節痛、腕隧道症候群、跗骨隧道症候群、腰椎術後疼痛症候群、愛滋病、動脈硬化、氣喘、關節炎、糖尿病、發炎性大腸炎、肝炎、腦中風、失智症、肌肉消耗、病毒感染、含光老化之皮膚老化、癌、及老化所成之群中。
[12]如[10]或[11]之預防或治療劑,其中相對於如前述[8]記載之群A’之甲氧基黃酮、與如[9]記載之群B’之甲氧基黃酮的總含量而言,群A’之甲氧基黃酮之總含量的比例(A’/(A’+B’)),以莫耳基準計係超過0.48。
[13]一種NOX抑制劑,其係含有3’,4’-二甲氧基黃酮。
[14]一種起因於NOX之疾病的預防或治療劑,其係含有3’,4’-二甲氧基黃酮。
[15]如[14]之預防或治療劑,其中前述疾病係選自由過敏疾病、巴金森症、腦梗塞、白內障、癲癇、脊髓損傷、動脈硬化、早產兒視網膜病變、腎病變、消化性潰瘍、胰臟炎、潰瘍性大腸炎、心肌梗塞、成人呼吸窘迫症候群、肺氣腫、慢性類風濕性關節炎等之膠原病、血管炎、浮腫、糖尿病併發症、紫外線損害、高山症、卟啉血症、燒燙傷、凍傷、接觸性皮膚炎、休克、多重器官衰竭、DIC、癌、老化、疲勞、肌肉減少症(肌力低下)、粒線體功能失調、失智症、及阿茲海默症所成之群中。
本發明可提供具有優良作用之NOX抑制劑及NFκB抑制劑。又,利用其亦可提供起因於NOX或NFκB之疾病的預防或治療劑。
本發明中使用之甲氧基黃酮,與以往被發現具有抗氧化作用等之甲氧基黃酮不同,即使不具有羥基,亦顯示優良的NOX抑制等之作用。
本發明中,係使用具有以下之式(I)
(式中,R1、R4、及R5,各自獨立地為氫或甲
氧基,R2及R3為甲氧基)表示之構造的至少1種、較佳為至少2種、更佳為至少3種、更佳為至少4種、更佳為至少5種、更佳為至少6種、更佳為至少7種、更佳為至少8種之甲氧基黃酮。
本發明之NOX抑制、或起因於NOX之疾病
的治療或預防中,較佳為,前述至少1種甲氧基黃酮,係選自由5,7,3’,4’-四甲氧基黃酮、3,5,7,3’,4’-五甲氧基黃酮、5,7-二甲氧基黃酮、及5,7,4’-三甲氧基黃酮所成之群A中。NOX抑制劑、或起因於NOX之疾病的治療或預防劑,不僅群A之甲氧基黃酮,亦可含有其他化合物,例如來自黑薑之選自由3,5,7-三甲氧基黃酮、3,5,7,4’-四甲氧基黃酮、5-羥基-3,7,3’,4’-四甲氧基黃酮、5-羥基-7-甲氧基黃酮、5-羥基-7,4’-二甲氧基黃酮、5-羥基-3,7-二甲氧基黃酮、及5-羥基-3,7,4’-三甲氧基黃酮所成之群B的至少1種甲氧基黃酮。但是,群A之甲氧基黃酮,會顯示較群B之甲氧基黃酮更高的NOX抑制作用。因此,群A之甲氧基黃酮之含有率較高者為佳。例如,相對於群A及群B之甲氧基黃酮之總含量而言,群A之甲氧基黃酮之總含量的比例(A/(A+B)),以莫耳基準(或重量基準)計,較佳為超過0.65、更佳為0.66以上、更佳為0.67以上、更佳為0.68以上、更佳為0.69以上、更佳為0.70以上、更佳為0.71以上。該比例並無上限值,該比例亦可為1.00以下。
本發明之NFκB抑制、或起因於NFκB之疾病
的治療或預防中,較佳為,前述至少1種甲氧基黃酮,係選自由5,7,3’,4’-四甲氧基黃酮、5,7-二甲氧基黃酮、及5,7,4’-三甲氧基黃酮所成之群A’中。NFκB抑制劑、或起因於NFκB之治療或預防劑,不僅群A’之甲氧基黃酮,亦可含有其他化合物,例如來自黑薑之選自由3,5,7,3’,4’-五甲氧基黃酮、3,5,7-三甲氧基黃酮、3,5,7,4’-四甲氧基黃酮、5-羥基-3,7,3’,4’-四甲氧基黃酮、5-羥基-7-甲氧基黃酮、5-羥基-7,4’-二甲氧基黃酮、5-羥基-3,7-二甲氧基黃酮、及5-羥基-3,7,4’-三甲氧基黃酮所成之群B’的至少1種甲氧基黃酮。但是,群A’之甲氧基黃酮,會顯示較群B’之甲氧基黃酮更高的NFκB抑制作用。因此,群A’之甲氧基黃酮之含有率較高者為佳。例如,相對於群A’及群B’之甲氧基黃酮之總含量而言,群A’之甲氧基黃酮之總含量的比例(A’/(A’+B’)),以莫耳基準(或重量基準)計,較佳為超過0.48、更佳為0.49以上、更佳為0.50以上、更佳為0.51以上、更佳為0.52以上、更佳為0.53以上、更佳為0.54以上、更佳為0.55以上、更佳為0.60以上。該比例並無上限值,該比例亦可為1.00以下。
或者,甲氧基黃酮,係3’,4’-二甲氧基黃酮。
此等甲氧基黃酮之大部分,例如可遵照非專利文獻4記載之方法,由黑薑(Kaempferia parviflora)得到。或者,例如亦可遵照本說明書之實施例1所詳述之方法而得到。黑薑係屬於薑科之植物的一種,以東南亞為中心而自然生長,因此可容易獲得。3’,4’-二甲氧基黃酮,
已知例如可使用溶劑由Lawsonia alba(散沫花)萃取。例如請參照Phytochemistry Letters,2011,4,454-458。
前述抑制劑及治療或預防劑中所含之甲氧基
黃酮的種類及量,可依需要基於公知之方法來調整。例如,可使用公知之精製方法將特定之甲氧基黃酮去除,亦可將特定之經精製的甲氧基黃酮添加於前述抑制劑、或治療或預防劑中。
又,本發明中,亦可由黑薑中得到含式(I)之
甲氧基黃酮的油脂萃取物來利用。該油脂萃取物係由黑薑經油脂萃取而得之萃取物。該萃取物係含有甲氧基黃酮,而黑薑萃取物所特有之黑紫色的強度被減低。該萃取物亦可進一步含有油脂、特別是用於萃取之油脂。
該油脂萃取物,可認為與未由黑薑所得者、
或即使以黑薑為原料但未經油脂萃取而得者,在所含有之成分的種類及比率等之方面不同。例如,由黑薑以外之植物所得之萃取物亦可含有甲氧基黃酮,但其種類或比率可認為與該油脂萃取物不同。又,即使黑薑為原料,藉由油脂萃取以外之方法,例如含水醇萃取由其中所得之萃取物中的甲氧基黃酮之種類或比率,係與該油脂萃取物不同。
另一方面,油脂萃取可對黑薑直接進行,亦可間接地,例如對使用油脂以外之溶劑,例如水、親水性溶劑、或該等之混合物由黑薑所得之萃取液來進行。
該油脂萃取物,係含有至少1種之式(I)之甲
氧基黃酮。該甲氧基黃酮,較佳為由群A中選擇。該萃取
物亦可進一步含有由群B中選擇之甲氧基黃酮。該油脂萃取物,較佳為含有由群A及B之11種甲氧基黃酮中選擇的至少1種、更佳為至少2種、更佳為至少3種、更佳為至少4種、更佳為至少5種、更佳為至少6種、更佳為至少7種、更佳為至少8種、更佳為至少9種、更佳為至少10種、更佳為11種。
可使用於該油脂萃取物之製造,且可包含於
該萃取物中的油脂,只要可溶解甲氧基黃酮則無特殊限定。典型而言,該油脂係由中鏈脂肪酸三酸甘油酯、二酸甘油酯、芝麻沙拉油、橄欖油、大豆油、菜籽油、玉米油、米胚芽油、葵花籽油、紫蘇油、蘇子油中選出之至少1種。關於中鏈脂肪酸三酸甘油酯所使用的「中鏈脂肪酸」,意指碳數8~12之脂肪酸。構成該三酸甘油酯之脂肪酸部分當中的至少一個、較佳為二個、更佳為三個為中鏈脂肪酸。
該油脂萃取物中,黑紫色之強度減低。為了
確認此事,測定該萃取物之吸光度係有效的。
具體而言,係由該萃取物,配製群A及B之
11種甲氧基黃酮的總含量為5.0mg/ml的溶液,測定該溶液於波長660nm之吸光度。如此方式所測定之吸光度,於該油脂萃取物中係0.10以下。該吸光度較佳為0.07以下、更佳為0.05以下。若無特別指明,本說明書中之吸光度,意指比色槽長度(光徑長)為10mm時的吸光度。測定所用之裝置的比色槽長度不是10mm時,係將所得之吸
光度值換算為比色槽長度為10mm時的值。又,為了測定吸光度,係使用適切的空白試樣。
以下說明該油脂萃取物之製造方法。
例如,該製造方法包含使油脂與黑薑之植物
體接觸,而萃取1種以上之甲氧基黃酮。該方法之典型例子如以下記載。
首先,準備黑薑之植物體。將該植物體或其
部位依需要予以乾燥、粉碎。接著使該植物體或其部位與油脂接觸,進行萃取。萃取條件,只要係可萃取甲氧基黃酮,則無特殊限定。典型的萃取溫度,係50~180℃、70~170℃、70~150℃、100~150℃、或120~150℃。萃取時間,典型而言為1分~1日、10分~10小時、或15分~5小時。又,所使用之油脂的用量,典型而言係黑薑重量之0.1~30倍、或0.5~15倍。所用之油脂的例子,係如上述。
該萃取中,甲氧基黃酮移動至油脂,但黑薑
之產生黑紫色的成分,可認為係保留在黑薑之植物體中,然不為理論所限。又,產生黑薑特有之香味的成分,亦可認為不移動至油脂,而保留在該植物體中。
接著,進行萃取後,依需要由以該萃取所得
之含油脂萃取物中,藉由過濾或離心分離而去除不溶性固體物。
或者,油脂萃取物之製造,係包含使水、親
水性溶劑、或該等之混合物與黑薑之植物體接觸,萃取1
種以上之甲氧基黃酮,而後使油脂與由該萃取所得之中間萃取物接觸,來萃取該甲氧基黃酮。此方法之典型例子如以下記載。
首先,與上述相同地準備黑薑之植物體。接
著使水、親水性溶劑、或該等之混合物與該植物體或其部位接觸,進行萃取。萃取條件,只要係可萃取甲氧基黃酮,則無特殊限定。典型的萃取溫度,係室溫~回流溫度、40℃~回流溫度、50℃~回流溫度、回流溫度,較佳為50℃~回流溫度、或回流溫度。萃取時間,典型而言係1分~1日、10分~10小時、或15分~5小時。又,所使用之水、親水性溶劑或該等之混合物的用量,典型而言為黑薑之重量的0.1~30倍、或0.5~15倍。所使用之親水性溶劑,較佳為C1-3醇及/或丙酮、更佳為乙醇。例如,使用50~100v/v%乙醇進行萃取。將該萃取步驟中所得之中間萃取物,進行油脂萃取步驟。
油脂萃取步驟中,係使該中間萃取物與油脂
接觸,來進行萃取。萃取條件,只要係可萃取甲氧基黃酮,則無特殊限定。萃取溫度並無特殊限定,例如係於5℃以上、10℃以上、20℃以上、30℃以上、40℃、或50℃以上進行。萃取溫度之上限值並無特殊限制,只要係水、親水性溶劑或該等之混合物的回流溫度以下即可。萃取時間,典型而言為1分~1日、10分~10小時、或15分~5小時。又,所使用之油脂的用量,典型而言係黑薑重量之0.01~30倍、或0.1~15倍。所用之油脂的例子,係如
上述。
進一步地,依情況不同,於使油脂與該中間
萃取物接觸之前,及/或於該等接觸的當中,使水、親水性溶劑、或該等之混合物由該中間萃取物中蒸發。蒸發可在常壓下進行、亦可在減壓下進行。如此地進行積極蒸發的情況時,萃取時間不甚重要。只要蒸發進行,水、親水性溶劑或該等之混合物之量降低,則可認為甲氧基黃酮會移動至油脂中,又,依情況亦會與該親水性溶劑等一起移動至油脂中。
油脂萃取中,甲氧基黃酮會移動至油脂,但
黑薑之產生黑紫色的成分,可認為不移動至油脂,然不為理論所限。
接著,進行萃取後,依需要由以該萃取所得
之含油脂萃取物中,藉由過濾或離心分離去除不溶性固體物。此點中間萃取物亦相同。
依照前述2個方法,可得到含油脂萃取物。
此可不經進一步精製而使用,亦可依需要進行精製。例如,亦可將該含油脂萃取物進行進一步的萃取步驟,來去除油脂。具體而言,係使水、親水性溶劑、或該等之混合物與該含油脂萃取物接觸,來萃取1種以上之甲氧基黃酮。此時,若依需要,亦可於該含油脂萃取物中添加低極性溶劑,例如如n-己烷之C1-8烴。
所使用之親水性溶劑或親水性溶劑與水的混
合物之例子,係如上所述。萃取溫度並無特殊限定,例如
係於5℃以上、10℃以上、20℃以上、30℃以上、40℃、或50℃以上進行。萃取溫度之上限值並無特殊限制,只要係水、親水性溶劑或該等之混合物之回流溫度以下即可。萃取時間,典型而言為1分~1日、10分~10小時、或15分~5小時。又,所使用之水、親水性溶劑或該等之混合物之用量,典型而言,係油脂萃取物重量之0.01~30倍、或0.1~15倍。
進一步地,於甲氧基黃酮之萃取中,係得到
來自該含油脂萃取物之油脂相,與來自該水、親水性溶劑、或該等之混合物之相的2相混合物,將該混合物進行液-液分離。結果,可將該水、親水性溶劑、或該等之混合物之相(此係含有甲氧基黃酮與溶劑之萃取物),自油脂相中分離。為了進行液-液分離,例如,可單純將該2相混合物靜置、亦可進行離心分離。之後,得到經分離之萃取物。
經分離之萃取物,係含有甲氧基黃酮,且含
有溶劑之液體形態。可直接利用該液體,亦可去除溶劑(水、親水性溶劑、或其混合物),得到含有甲氧基黃酮之粉末形態的萃取物。去除溶劑之方法並無特殊限定,可列舉於常壓或減壓下之蒸餾、冷凍乾燥等。
如此方式經去除油脂的萃取物,係含有較高
濃度的黑薑特有之甲氧基黃酮。該萃取物亦可依需要進一步精製。
油脂萃取物中,與使用乙醇等之親水性溶劑
所得之萃取物比較,上述A/(A+B)及A’/(A’+B’)之比例較高。油脂萃取物中之該比例的較佳範圍,係如上述。
本發明者,發現式(I)之甲氧基黃酮,有效於作為NADPH氧化酶(NOX)抑制劑。因此,本發明之一個形態,係NOX抑制劑、或用以抑制NOX之組成物,其係含有至少一種式(I)之甲氧基黃酮(本說明書中,「NOX抑制劑」與「用以抑制NOX之組成物」,係相互交換地使用,若無特別指明,則使用其一方時,亦意指另一方)。
本發明於其他態樣中,亦為用以抑制NOX之方法,其係包含將式(I)之甲氧基黃酮的至少一種投與至對象。或者,取代式(I)之甲氧基黃酮,或對其追加地,亦可使用3’,4’-二甲氧基黃酮。
NOX之抑制,係導致預防或治療起因於NOX
之疾病。因此,本發明於其他形態中,係為起因於NOX之疾病的預防或治療劑、或用於該預防或治療之組成物,其係含有式(I)之甲氧基黃酮的至少1種(本說明書中,「起因於NOX之疾病的預防或治療劑」與「用以預防或治療起因於NOX之疾病的組成物」,係相互交換地使用,若無特別指明,則使用其一方時,亦意指另一方)。
本發明於其他態樣中,係為用以預防或治療該疾病之方法,其係包含將該甲氧基黃酮之至少1種投與至對象。如此之疾病,係包含異位性皮膚炎、過敏性鼻炎(花粉症)、
過敏性結膜炎、過敏性胃腸炎、支氣管氣喘、小兒氣喘、食物過敏、藥物過敏、蕁麻疹等之過敏疾病、巴金森症、腦梗塞、白內障、癲癇、脊髓損傷、動脈硬化、早產兒視網膜病變、腎病變、消化性潰瘍、胰臟炎、潰瘍性大腸炎、心肌梗塞、成人呼吸窘迫症候群、肺氣腫、慢性類風濕性關節炎等之膠原病、血管炎、浮腫、糖尿病併發症、紫外線損害、高山症、卟啉血症、燒燙傷、凍傷、接觸性皮膚炎、休克、多重器官衰竭、DIC、癌、老化、疲勞、肌肉減少症(肌力低下)、粒線體功能失調、失智症、及阿茲海默症。或者,取代式(I)之甲氧基黃酮,或對其追加地,亦可使用3’,4’-二甲氧基黃酮。
本發明於其他形態中,係含有至少一種式(I)
之甲氧基黃酮的抗氧化劑(更具體而言,係生體內抗氧化、抑制或減低劑)、或用以防止、抑制或減低生體內氧化之組成物(本說明書中,「抗氧化劑」、「生體內抗氧化、抑制或減低劑」、「用以防止、抑制或減低生體內氧化之組成物」,係相互交換地使用,若無特別指明,則記載此等三者之一時,亦意指其餘之二者)。本發明於其他態樣中,係為用以防止、抑制或減低生體內氧化之方法,其包含將式(I)之甲氧基黃酮的至少一種投與至對象。本說明書中,生體內氧化,意指於生體內因活性氧而產生之各種氧化反應。或者,取代式(I)之甲氧基黃酮,或對其追加地,亦可使用3’,4’-二甲氧基黃酮。
本發明之NOX抑制劑、起因於NOX之疾病
的預防或治療劑、抗氧化劑中之式(I)之甲氧基黃酮的總含量,只要可得到所期望之效果,則無特殊限定,較佳為0.01~50w/w%、更佳為0.1~40w/w%、更佳為0.5~30w/w%。
為了發揮NOX抑制作用、起因於NOX之疾
病的預防或治療、抗氧化等之前述所期望之效果,成人每1日之式(I)的甲氧基黃酮之總攝取量,較佳為1~500mg、更佳為3~200mg、又更佳為5~100mg。
上述量亦可適用於3’,4’-二甲氧基黃酮。
本發明者,發現了式(I)之甲氧基黃酮係有效於作為NFκB抑制劑。因此,本發明於其他形態中,係NFκB抑制劑、或用以抑制NFκB之組成物,其係含有至少一種之式(I)之甲氧基黃酮(本說明書中,「NFκB抑制劑」與「用以抑制NFκB之組成物」係相互交換地使用,若無特別指明,則則使用其一方時,亦意指另一方)。本發明於其他態樣中,係為用以抑制NFκB之方法,其係包含將式(I)之甲氧基黃酮的至少一種投與至對象。或者,取代式(I)之甲氧基黃酮,或對其追加地,亦可使用3’,4’-二甲氧基黃酮。
NFκB之抑制,係導致預防或治療起因於
NFκB之疾病。因此,本發明於其他形態中,係為起因於NFκB之疾病的預防或治療劑、或用於該預防或治療之組
成物,其係含有式(I)之甲氧基黃酮的至少1種(本說明書中,「起因於NFκB之疾病的預防或治療劑」與「用於起因於NFκB之疾病的預防或治療劑之組成物」係相互交換地使用,若無特別指明,則則使用其一方時,亦意指另一方)。本發明於其他態樣中,係關於用以預防或治療該疾病之方法,其係包含將該甲氧基黃酮之至少1種投與至對象。如此之疾病,係包含類風濕性關節炎、發炎性大腸炎、變形性關節症、骨溶解症、腱炎、坐骨神經痛、椎間盤突出、狹窄症、脊髓症、腰痛、椎間關節痛、腕隧道症候群、跗骨隧道症候群、腰椎術後疼痛症候群、愛滋病、動脈硬化、氣喘、關節炎、糖尿病、發炎性大腸炎、肝炎、腦中風、失智症、肌肉消耗、病毒感染、含光老化之皮膚老化、癌、及老化。或者,取代式(I)之甲氧基黃酮,或對其追加地,亦可使用3’,4’-二甲氧基黃酮。
本發明之NFκB抑制劑、起因於NFκB之疾病
的預防或治療劑中之式(I)的甲氧基黃酮之總含量,只要可得到所期望之效果,則無特殊限定,較佳為0.01~50w/w%、更佳為0.1~40w/w%、更佳為0.5~30w/w%。
為了發揮NFκB抑制作用、起因於NFκB之疾
病的預防或治療等之前述所期望的效果,成人每1日之式(I)甲氧基黃酮的總攝取量,較佳為1~500mg、更佳為3~200mg、又更佳為5~100mg。
上述之量亦可適用於3’,4’-二甲氧基黃酮。
本發明之NOX或NFκB抑制劑、起因於NOX或NFκB之疾病的預防或治療劑、抗氧化劑,只要不損及其效果,於式(I)之甲氧基黃酮以外,亦可摻合任意成分。例如,可適當摻合維生素E、維生素C等之維生素類;礦物質類、荷爾蒙、營養成分、香料等之生理活性成分,此外可適當摻合製劑化中摻合的乳化劑、張力化劑(等張化劑)、緩衝劑、溶解輔助劑、防腐劑、安定化劑等。
本發明之NOX或NFκB抑制劑、起因於NOX或NFκB之疾病的預防或治療劑、抗氧化劑,可使用作為飲食品(機能性食品、健康輔助食品、營養機能食品、特別用途食品、特定保健用食品、營養輔助食品、飲食療法用食品、健康食品、補充劑等)、醫藥品、或化妝香料品;或其原料。飲食品及醫藥品,亦可為加工為寵物飼料的寵物食品或動物飼料等、以及動物用醫藥品。
該飲食品之形態並無特殊限定,可為例如清
涼飲料水(例如運動飲料、碳酸飲料、果汁飲料)、甜點類(例如蛋糕、餅乾、麵包、糖果)、麵類(例如烏龍麵、蕎麥麵、日本拉麵、義大利麵)、味噌、醬油、醋、沙拉油、芝麻油、豆乳、牛乳。或者錠劑、顆粒劑、散劑、膠囊劑(亦包含軟膠囊)等之形態。
該醫藥品之形態並無特殊限定,例如為外用
劑(例如洗劑、乳液劑、貼附劑、軟膏劑)、經口劑(錠劑、顆粒劑、散劑、膠囊劑(亦包含軟膠囊)、溶液劑、懸浮液劑)、注射劑、注入劑。
該化妝香料品之形態,並無特殊限定,例如
為化粧水、凝膠、洗劑、乳霜、面膜劑、乳液、粉底、口紅、粉末、洗面劑、髮油。
為了明確化而記載時,本說明書中以下限值與上限值所表示之數值範圍,亦即「下限值~上限值」,係包含該等之下限值及上限值。例如,以「1~2」所表示之範圍,係包含1及2。
對黑薑150g添加50%乙醇水溶液1500ml,進行2小時加熱回流萃取。冷卻後過濾所得之萃取液,於減壓下濃縮,進行冷凍乾燥,得到黑薑萃取物25.7g。將所得萃取物當中之9g,進行使用了Dia ion HP20(三菱化學股份有限公司製)之管柱層析,分為4個區分(30%乙醇溶出部、50%乙醇溶出部、70%乙醇溶出部、100%乙醇溶出部)。將其中之50%乙醇溶出部進行高速液體層析,單離出
5,7,3’,4’-四甲氧基黃酮(64mg)、3,5,7,3’,4’-五甲氧基黃酮(464mg)、5,7-二甲氧基黃酮(145mg)、5,7,4’-三甲氧基黃酮(188mg)、3,5,7-三甲氧基黃酮(35mg)、3,5,7,4’-四甲氧基黃酮(96mg)。接著對100%乙醇溶出部亦同樣地以液體層析進行分離精製,單離出5-羥基-3,7,3’,4’-四甲氧基黃酮(15mg)、5-羥基-7-甲氧基黃酮(84mg)、5-羥基-7,4’-二甲氧基黃酮(56mg)、5-羥基-3,7-二甲氧基黃酮(100mg)、5-羥基-3,7,4’-三甲氧基黃酮(110mg)。單離之化合物,係將其頻譜數據與文獻(大阪市立大學生活科學研究科 東銳明氏博士論文「薑科植物Kaempferia parviflora中所含的成分之構造與α-葡萄糖苷酶抑制活性及抗突變性」)所記載之各種頻譜數據比較,並進行鑑定。
對3g及15g之黑薑分別添加橄欖油30mL,於120℃進行30分鐘萃取後,冷卻後過濾,得到2種淡黃色之黑薑油脂萃取物。由以下之分析條件,將所得2種油脂萃取物中之實施例1記載之甲氧基黃酮11種的總含量予以定量後,其值為6.2mg/mL(由3g之黑薑)、22.4mg/mL(由15g之黑薑)。再者,此等萃取物均含有實施例1記載之甲氧基黃酮全部11種。
對黑薑油脂萃取物1.0mL添加n-己烷1.0mL予以稀釋後,以2.0mL之80%甲醇水溶液進行甲氧基黃酮之萃取3次。將所得之80%甲醇萃取液通過Mega Bond Elute C18(Agilent Technologies公司製)後,以洗出吸附於Mega Bond Elute C18之甲氧基黃酮為目的,通過80%甲醇2.0mL。合併所得之液體後,最終定量為10mL,作為HPLC用之分析試樣。
管柱:Develosil C30 UG5(4.6×150mm、5μm、野村化學股份有限公司製)
檢測:280nm(PDA為200~600nm)
管柱溫度:40℃
移動相A:0.05%三氟乙酸水溶液
移動相B:90%乙腈水溶液中之三氟乙酸0.05%溶液
梯度:移動相B 50%-50%-70%-70%(0min-7.5min-20min-25min)
流速:1.0mL/min
試樣注入量:10μL
人類骨髓性白血病細胞HL-60細胞於未分化狀態會重
複增殖,但已知藉由添加DMSO(dimethyl sulfoxide)或視黃酸等,會分化為成熟顆粒球,喪失增殖能力,而且亦為分化指標之NOX(NADPH oxidase)會於細胞內表現,該NOX可利用作為用以評估NOX抑制活性之酵素源。
為了分化為表現NOX之顆粒球,將以含有
10% FBS之RPMI1640培養基培養之未分化HL-60細胞,懸浮於含1% DMSO之含有10% FBS之RPMI1640培養基中,使成為5×105cells/ml,將該懸浮液於內徑10cm之培養皿中各分注15ml,於CO2培養箱(37℃)中培養3日後,於各培養皿中追加10ml之含1%DMSO之含有10%FBS之RPMI1640培養基,進一步培養3日,藉此可得到表現了NOX之經分化的HL-60細胞。如以下記載般,使用經分化之HL-60細胞之細胞破碎液或直接使用活細胞,來測定NOX活性。
使用細胞破碎液以cell-free系進行之NOX活性測定:藉由離心處理來收集經DMSO處理而分化之HL-60細胞,以PBS(磷酸緩衝生理食鹽水)洗淨一次後,使用細胞破碎用之緩衝液(含有131mM NaCl及340mM sucrose之8mM磷酸緩衝液pH7.0),懸浮成為1×108cells/ml。使其冰冷後,使用超音波破碎機(Bioruptor UCD-250HSA、Cosmo Bio製),於4℃以下之條件,重複「最大輸出之破碎20秒/休止期冷卻30秒」的程序3次,藉以得到細胞破碎液。將破碎液1000g、4分鐘之離心處
理,以去除debris,於所得之上清液中添加9倍容積之反應用緩衝液(含有1mM EGTA、10μM FAD及170mM sucrose之65mM磷酸緩衝液pH7.0),配製NOX測定用之細胞破碎上清液(相當於1×107cells/ml)。
NOX之反應,係於96well之微孔盤中,每
well注入50μl之上述細胞破碎液,進一步添加NOX活性化劑之0.5mM SDS溶液25μl、基質之0.4mM NADPH溶液25μl,於25℃進行30~90分鐘。NOX活性係藉由以螢光測定(Ex:355nm/Em:460nm)NADPH之消耗速度來求得。
被測樣品之NOX抑制活性,係配製樣品之
DMSO溶液(試藥的情況時通常為10mM),藉由DMSO配製3倍系列稀釋之溶液,將其於上述反應液中各添加1μl/well,進行酵素反應,所得之抑制活性係以IC50值(μM、萃取物的情況時為μg/ml)表示。
使用經分化之HL-60活細胞的NOX活性測定:藉由離心處理來收集經DMSO處理而分化之HL-60細胞,懸浮於不含FBS及酚紅之D-MEM培養基中,成為5×106cells/ml。NOX之反應,係於96well之微孔盤中每well注入25μl之上述細胞懸浮液,進一步地各自添加25μl之使用上述D-MEM所配製之0.8mg/ml WST-1溶液、配製為特定濃度之被測樣品溶解液(配製樣品之DMSO溶液(試藥的情況時通常為10mM),自此開始使用
DMSO配製3倍系列稀釋之溶液,將其溶解於上述D-MEM,成為1v/v%以下,來配製該被測樣品溶解液)並攪拌後,添加25μl之4μM PMA(Phorbol 12-Myristate 13-acetate、終濃度為1μM)D-MEM溶液,進行NOX之活性化,於37℃進行反應45分鐘,以450nm吸光度來測定NOX酵素生成物的超氧化物與反應液中之WST-1進行反應所生成之黃色甲(formazan)。再者,該NOX活性測定系統中,確認了只要未添加PMA,則NOX不會活性化。
所得之抑制活性係以IC50值(μM、萃取物的
情況時為μg/ml)表示。
遵照實施例3,藉由以使用了細胞破碎液之cell-free系統來進行NOX活性測定,比較數個甲氧基類黃酮之NOX抑制活性。結果示於表1。
如表1所示,於葉黃酮(luteolin)之甲氧基體的5,7,3’,4’-四甲氧基黃酮,或槲黃素之甲氧基體的3,5,7,3’,4’-五甲氧基黃酮等,觀察到強的NOX抑制活性。此等之5,7-二甲氧基類黃酮類係含有於黑薑等中。另一方面,於已知存在於柑橘類之陳黃皮酮等之六甲氧基黃酮,未觀察到強的NOX抑制活性。再者,NOX抑制劑的VAS2870之使用該細胞破碎液以cell-free系統所得之IC50值,係3.3μM。
遵照實施例3,藉由以使用了cell-free系統之NOX活性測定來比較由黑薑萃取/分離之甲氧基類黃酮之NOX抑制活性。由黑薑所得到之類黃酮均具有具備甲氧基之特
徵。其中,於A環之5號位置與7號位置具有甲氧基之黃酮,觀察到強的NOX抑制活性,但於5號位置具有羥基之類黃酮,未觀察到NOX抑制活性。3號位置之甲氧基雖非致命性的,但可見活性減弱的傾向。因此,式(I)表示之甲氧基黃酮,可認為具有優良的NOX抑制活性。又,該系統中之VAS2870(NOX抑制劑)之IC50為6.3μM。
為了確認黑薑之批次所致之油脂萃取物之組成的相異,準備2種之黑薑200g,分別添加乙醇1000mL,進行1小時加熱回流萃取。將所得液體冷卻後,吸引過濾,分為殘渣與萃取液。再度於殘渣中添加乙醇1000mL,進行1小時加熱回流萃取並過濾,與先前所得之萃取液合併。
接著於萃取液中添加中鏈脂肪酸三酸甘油酯100mL,以減壓濃縮餾去乙醇後,藉由吸引過濾去除所析出之不溶物,得到2種黑薑油脂萃取物。根據實施例2,分析該等萃取物中之甲氧基黃酮含量後,甲氧基黃酮總量係90.4mg/mL(以下將此萃取物稱為「萃取物A」)、54.9mg/mL(以下將此萃取物稱為「萃取物B」)。又,將此等2種萃取物中之甲氧基黃酮總量以橄欖油調節為5mg/ml,得到2種溶液,測定該溶液於660nm之吸光度後,分別為0.036(萃取物A)、0.030(萃取物B)(使用甲醇作為空白試樣)。再者,此等萃取物均含有實施例1記載之全部11種之甲氧基黃酮。
對黑薑乾燥物200g添加50%乙醇水溶液1000mL,進行1小時加熱回流萃取。將所得之液體冷卻後,吸引過濾,分為殘渣與萃取液。再度於殘渣中添加50%乙醇水溶液1000mL,進行1小時加熱回流萃取並過濾,與先前所得之萃取液合併。冷卻至室溫後,減壓濃縮之後,進行冷凍乾燥,得到49g黑薑乙醇萃取物-1(產率24.5%)。以確認黑薑之批次間所致的差異為目的,以與上述相同之方法進行操作後,得到23g黑薑乙醇萃取物-2(產率15.2%)。接著,根據實施例2之方法,測定本萃取物中之11種甲
氧基黃酮總含量後,分別為264mg/g、267mg/g。將黑薑乙醇萃取物-1中之甲氧基黃酮總量以甲醇調節為5mg/ml,得到溶液,測定該溶液於660nm之吸光度後,其係0.95(空白試樣為甲醇)。再者,此等萃取物均含有實施例1記載之全部11種之甲氧基黃酮。
對黑薑10g、20g、30g、40g,分別添加10倍量之乙醇,進行1小時加熱回流萃取。將所得之液體冷卻後,吸引過濾,於該萃取液中添加中鏈脂肪酸三酸甘油酯15mL,藉由減壓濃縮餾去乙醇後,以去除不溶物為目的再度進行吸引過濾,得到各自之黑薑油脂萃取物。對所得之4種黑薑油脂萃取物,根據實施例2,分析11種甲氧基黃酮之總含量後,其值分別為23.9mg/mL、46.3mg/mL、69.4mg/mL、78.1mg/mL。又,將總甲氧基黃酮量含有46.3mg/mL以上之油脂萃取物,於室溫下放置時,確認到甲氧基黃酮類之析出。再者,此等萃取物均含有實施例1記載之全部11種之甲氧基黃酮。
遵照實施例3,測定總甲氧基黃酮量22.4mg/ml之黑
薑油脂萃取物-1(實施例2中所得到者)、總甲氧基黃酮量69.4mg/ml之黑薑油脂萃取物-2(實施例8中所得到者)、乙醇萃取物(實施例7中所得到之黑薑乙醇萃取物-1及2)的NOX抑制活性(使用經分化之HL-60活細胞的NOX抑制活性測定)。為了觀察黑薑之批次間的活性強度的不同,探討2種黑薑。又,油脂萃取物無法直接測定活性,因此進行脫脂處理。具體而言,對油脂萃取物0.5mL添加同量之n-己烷0.5mL進行稀釋後,以0.5mL之80%甲醇水溶液進行3次甲氧基黃酮之萃取。將所得之萃取液吸附於Sep-Pak PLUS C8 125Å Catrtriges(Waters公司製),進一步通過80%甲醇3.0mL去除油分。之後,以溶劑洗淨Sep-Pak PLUS C8 125Å Catrtriges,將所得液體減壓濃縮、冷凍乾燥,配製評価試樣。所測定之IC50值示於以下之表3。
以下所示之IC50值,係表示基於總甲氧基黃
酮量之NOX抑制活性。比較該等之值後,油脂萃取物均較乙醇萃取物顯示較高之作用(低的IC50)。由此,顯示藉由如本發明般以油脂萃取,會有效率地萃取出對NOX抑制作用更高的甲氧基黃酮。
已知將類巨噬細胞之RAW264.7細胞以LPS(脂多醣)刺激時,NFκB被活性化,藉此iNOS(誘導型NO合成酵素)之表現亢進,起因於iNOS酵素活性之亞硝酸會於培養液中累積,藉由測定培養液中之亞硝酸量,可評估NFκB活性化。
RAW264.7細胞係使用於含有10%FBS之RPMI1640培養液中培養者。將所得之細胞懸浮於上述培養液,使成為4×105cells/ml,於96well微孔盤中,每well各分注100μl,預先(於CO2培養箱中)培養24hr。於其中,每well各自添加25μl之含有6μg/ml LPS之培養液(LPS係來自大腸菌,終濃度為1μg/ml)及25μl之特定濃度之被測標準品溶液,進一步培養24hr後,各自分取75μl之細胞培養液,藉由添加等量之Griess試藥(Fluka製),進行呈色反應,基於540nm之吸光度測定亞硝酸之生成。被測樣品之NFκB抑制活性的測定,係使用將樣品之DMSO溶液溶解於上述培養液中使DMSO濃度為1%以下的3倍系列稀釋之溶液來進行,測定刺激劑之LPS無添加/添加條件下的吸光度。表4表示起因於LPS刺激之亞硝酸生成被抑制50%之濃度、亦即IC50值(μM)。如表4所示,式(I)之甲氧基黃酮,顯示優良的NFκB抑制作用。
有鑑於實施例9之結果,比較來自黑薑之油脂萃取物與親水性溶劑萃取物的組成。具體而言,係根據實施例2、6及8,進行油脂萃取(僅以油脂萃取、或乙醇萃取與隨後的油脂萃取),根據實施例7進行乙醇萃取。油脂萃取中,係使用橄欖油、或橄欖油與中鏈脂肪酸甘油酯(本實施例中,係使用中鏈脂肪酸三酸甘油酯,其亦表示為「MCT」)的混合物,作為油脂。將所得之萃取物基於實施例2記載之方法以HPLC分析,將所得之HPLC面積值如以下表示。以下之表中,為了方便,亦有單將油脂表示為「Oil」者。
如表5A及5B所示,油脂萃取物中,NOX抑
制活性或NFκB抑制活性高的甲氧基黃酮之比例,亦即A/(A+B)及A’/(A’+B’),係較乙醇萃取物更高。如此之組成的不同,可影響NOX抑制活性或NFκB抑制活性。
Claims (15)
- 一種NOX抑制劑,其係含有具有以下之式(I)
- 如請求項1之NOX抑制劑,其中前述至少1種甲氧基黃酮,係選自由5,7,3’,4’-四甲氧基黃酮、3,5,7,3’,4’-五甲氧基黃酮、5,7-二甲氧基黃酮、及5,7,4’-三甲氧基黃酮所成之群A中。
- 如請求項2之NOX抑制劑,其中相對於群A之甲氧基黃酮;與由3,5,7-三甲氧基黃酮、3,5,7,4’-四甲氧基黃酮、5-羥基-3,7,3’,4’-四甲氧基黃酮、5-羥基-7-甲氧基黃酮、5-羥基-7,4’-二甲氧基黃酮、5-羥基-3,7-二甲氧基黃酮、及5-羥基-3,7,4’-三甲氧基黃酮所成之群B之甲氧基黃酮的總含量而言,群A之甲氧基黃酮之總含量的比例(A/(A+B)),以莫耳基準計係超過0.65。
- 一種起因於NOX之疾病的預防或治療劑,其係含 有如請求項1或2記載之至少1種甲氧基黃酮。
- 如請求項4之預防或治療劑,其中前述疾病係選自由過敏疾病、巴金森症、腦梗塞、白內障、癲癇、脊髓損傷、動脈硬化、早產兒視網膜病變、腎病變、消化性潰瘍、胰臟炎、潰瘍性大腸炎、心肌梗塞、成人呼吸窘迫症候群、肺氣腫、慢性類風濕性關節炎等之膠原病、血管炎、浮腫、糖尿病併發症、紫外線損害、高山症、卟啉血症、燒燙傷、凍傷、接觸性皮膚炎、休克、多重器官衰竭、DIC、癌、老化、疲勞、肌肉減少症(肌力低下)、粒線體功能失調、失智症、及阿茲海默症所成之群中。
- 如請求項4或5之預防或治療劑,其中相對於如請求項2記載之群A之甲氧基黃酮、與如請求項3記載之群B之甲氧基黃酮的總含量而言,群A之甲氧基黃酮之總含量的比例(A/(A+B)),以莫耳基準計係超過0.65。
- 一種NFκB抑制劑,其係含有具有以下之式(I)
- 如請求項7之NFκB抑制劑,其中前述至少1種甲氧基黃酮,係選自由5,7,3’,4’-四甲氧基黃酮、5,7-二甲氧基黃酮、及5,7,4’-三甲氧基黃酮所成之群A’中。
- 如請求項8之NFκB抑制劑,其中相對於群A’之甲氧基黃酮;與由3,5,7,3’,4’-五甲氧基黃酮、3,5,7-三甲氧基黃酮、3,5,7,4’-四甲氧基黃酮、5-羥基-3,7,3’,4’-四甲氧基黃酮、5-羥基-7-甲氧基黃酮、5-羥基-7,4’-二甲氧基黃酮、5-羥基-3,7-二甲氧基黃酮、及5-羥基-3,7,4’-三甲氧基黃酮所成之群B’之甲氧基黃酮的總含量而言,群A’之甲氧基黃酮之總含量的比例(A’/(A’+B’)),以莫耳基準計係超過0.48。
- 一種起因於NFκB之疾病的預防或治療劑,其係含有如請求項7或8記載之至少1種甲氧基黃酮。
- 如請求項10之預防或治療劑,其中前述疾病係選自由類風濕性關節炎、發炎性大腸炎、變形性關節症、骨溶解症、腱炎、坐骨神經痛、椎間盤突出、狹窄症、脊髓症、腰痛、椎間關節痛、腕隧道症候群、跗骨隧道症候群、腰椎術後疼痛症候群、愛滋病、動脈硬化、氣喘、關節炎、糖尿病、發炎性大腸炎、肝炎、腦中風、失智症、肌肉消耗、病毒感染、含光老化之皮膚老化、癌、及老化所成之群中。
- 如請求項10或11之預防或治療劑,其中相對於如請求項8記載之群A’之甲氧基黃酮、與如請求項9記 載之群B’之甲氧基黃酮的總含量而言,群A’之甲氧基黃酮之總含量的比例(A’/(A’+B’)),以莫耳基準計係超過0.48。
- 一種NOX抑制劑,其係含有3’,4’-二甲氧基黃酮。
- 一種起因於NOX之疾病的預防或治療劑,其係含有3’,4’-二甲氧基黃酮。
- 如請求項14之預防或治療劑,其中前述疾病係選自由過敏疾病、巴金森症、腦梗塞、白內障、癲癇、脊髓損傷、動脈硬化、早產兒視網膜病變、腎病變、消化性潰瘍、胰臟炎、潰瘍性大腸炎、心肌梗塞、成人呼吸窘迫症候群、肺氣腫、慢性類風濕性關節炎等之膠原病、血管炎、浮腫、糖尿病併發症、紫外線損害、高山症、卟啉血症、燒燙傷、凍傷、接觸性皮膚炎、休克、多重器官衰竭、DIC、癌、老化、疲勞、肌肉減少症(肌力低下)、粒線體功能失調、失智症、及阿茲海默症所成之群中。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014-097875 | 2014-05-09 | ||
JP2014097875 | 2014-05-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201625574A true TW201625574A (zh) | 2016-07-16 |
TWI700278B TWI700278B (zh) | 2020-08-01 |
Family
ID=54392533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW104114409A TWI700278B (zh) | 2014-05-09 | 2015-05-06 | 含有甲氧基黃酮之NOX抑制劑及NFκB抑制劑 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20170071902A1 (zh) |
JP (3) | JP2015227329A (zh) |
KR (1) | KR20170002565A (zh) |
CN (1) | CN106456597A (zh) |
AU (1) | AU2015256997B2 (zh) |
CA (1) | CA2948127A1 (zh) |
SG (2) | SG10201808940WA (zh) |
TW (1) | TWI700278B (zh) |
WO (1) | WO2015170683A1 (zh) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017145221A (ja) * | 2016-02-18 | 2017-08-24 | 株式会社レーネ | Tauタンパク質凝集阻害剤 |
JP6909559B2 (ja) * | 2016-03-31 | 2021-07-28 | 株式会社アンチエイジングコミュニケーション | Oph活性増強剤 |
JP6462755B2 (ja) * | 2017-04-04 | 2019-01-30 | 丸善製薬株式会社 | 脳の機能改善剤および脳の機能改善用飲食品 |
TWI646943B (zh) * | 2017-12-08 | 2019-01-11 | 財團法人自行車暨健康科技工業研究發展中心 | Method for screening for muscular dysfunction through functional fitness |
KR102032739B1 (ko) * | 2018-01-31 | 2019-10-16 | 한림대학교 산학협력단 | 신규한 크리신 유도체 화합물을 유효성분으로 포함하는 당뇨합병증의 예방 또는 치료용 약학 조성물 |
CN110237066B (zh) * | 2018-03-07 | 2022-03-29 | 上海市生物医药技术研究院 | 3-甲氧基黄酮及其衍生物在制备治疗或预防肾病的药物中的应用 |
CN108904489A (zh) * | 2018-06-19 | 2018-11-30 | 杭州勃锐思莫生物医药科技有限责任公司 | 5,7-甲氧基3,4’羟基黄酮的抗呼吸道炎症性疾病的用途 |
JP7229513B2 (ja) * | 2018-10-16 | 2023-02-28 | 丸善製薬株式会社 | 脳の機能改善剤および脳の機能改善用飲食品 |
CN109288834A (zh) * | 2018-11-28 | 2019-02-01 | 武汉科技大学 | 5-甲氧基黄酮在制备无义突变通读药物中的应用 |
WO2020178267A1 (en) * | 2019-03-04 | 2020-09-10 | Universite D'aix-Marseille | Nox inhibitors for preventing epileptic seizures |
CN110357846B (zh) * | 2019-07-11 | 2021-06-15 | 上海健康医学院 | 一种黄酮并单萜类化合物及其制备方法和应用 |
US20230021051A1 (en) * | 2019-12-26 | 2023-01-19 | Maruzen Pharmaceuticals Co., Ltd. | Composition Containing Black Ginger Extract and Composition for Oral Administration |
CN111374970B (zh) * | 2020-03-17 | 2023-05-30 | 广西壮族自治区中医药研究院 | 一种具有抗结肠炎活性的组合物及其应用 |
CN111617076B (zh) * | 2020-06-24 | 2021-09-28 | 江苏吴中医药集团有限公司 | 一种含有盐酸阿比多尔的复方药物组合物及其用途 |
JP7081843B2 (ja) * | 2020-10-26 | 2022-06-07 | 株式会社東洋新薬 | 自律神経調節剤 |
WO2022137964A1 (ja) * | 2020-12-23 | 2022-06-30 | 国立大学法人大阪大学 | 軟骨・骨・関節疾患の予防または治療用医薬組成物および軟骨・骨・関節疾患の予防または治療用薬剤のスクリーニング方法 |
WO2023144742A1 (en) | 2022-01-26 | 2023-08-03 | Universidade De Aveiro | Ionic-liquid-based formulations for the prevention or treatment of neurological diseases |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0210391A (pt) * | 2001-06-12 | 2004-06-15 | Elan Pharm Inc | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto |
JP2007314468A (ja) * | 2006-05-25 | 2007-12-06 | Meiji Milk Prod Co Ltd | 小胞体ストレス制御化合物とそれを有効成分とする医薬組成物 |
JP2009051790A (ja) * | 2007-08-29 | 2009-03-12 | Maruzen Pharmaceut Co Ltd | 抗酸化剤、抗老化剤、抗炎症剤、育毛剤、抗肥満剤、及び美白剤、並びに化粧料及び美容用飲食品 |
JP5756264B2 (ja) * | 2010-05-06 | 2015-07-29 | 日本タブレット株式会社 | キサンチンオキシダーゼ阻害剤、キサンチンオキシダーゼ及び5α−レダクターゼ阻害剤、並びに該阻害剤を含有する医薬組成物 |
KR101811303B1 (ko) * | 2011-07-26 | 2017-12-26 | 에스케이하이닉스 주식회사 | 반도체 집적회로 및 그의 구동 방법 |
US9745279B2 (en) * | 2011-12-27 | 2017-08-29 | Tokiwa Phytochemical Co., Ltd. | Sirtuin activator |
JP2013144659A (ja) * | 2012-01-16 | 2013-07-25 | Nippon Tablet Kk | 5α−レダクターゼ阻害剤、並びに該阻害剤を含有する飲食品類、化粧料組成物、医薬組成物 |
KR101528023B1 (ko) * | 2012-05-16 | 2015-06-15 | 연세대학교 산학협력단 | 캠페리아 파비플로라 추출물 또는 플라본계 화합물을 함유하는 근육 질환 예방 및 치료용 또는 근 기능 개선용 조성물 |
JP2013241354A (ja) * | 2012-05-18 | 2013-12-05 | Oriza Yuka Kk | ホスホジエステラーゼ2阻害剤 |
JP2013253047A (ja) * | 2012-06-07 | 2013-12-19 | Kinki Univ | 血液レオロジー改善剤、並びに該血液レオロジー改善剤を含有する飲食品類及び医薬組成物 |
WO2013185301A1 (zh) * | 2012-06-13 | 2013-12-19 | Jin Yongri | 黄酮及二氢黄酮衍生物在制备镇静、催眠药物中的用途 |
-
2015
- 2015-05-01 CA CA2948127A patent/CA2948127A1/en not_active Abandoned
- 2015-05-01 WO PCT/JP2015/063100 patent/WO2015170683A1/ja active Application Filing
- 2015-05-01 JP JP2015093939A patent/JP2015227329A/ja active Pending
- 2015-05-01 SG SG10201808940WA patent/SG10201808940WA/en unknown
- 2015-05-01 SG SG11201609248WA patent/SG11201609248WA/en unknown
- 2015-05-01 JP JP2016517902A patent/JP6666837B2/ja active Active
- 2015-05-01 CN CN201580024156.6A patent/CN106456597A/zh active Pending
- 2015-05-01 KR KR1020167034094A patent/KR20170002565A/ko not_active Application Discontinuation
- 2015-05-01 US US15/308,868 patent/US20170071902A1/en not_active Abandoned
- 2015-05-01 AU AU2015256997A patent/AU2015256997B2/en not_active Ceased
- 2015-05-06 TW TW104114409A patent/TWI700278B/zh active
-
2019
- 2019-12-19 JP JP2019228987A patent/JP7015822B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
AU2015256997A1 (en) | 2016-11-24 |
TWI700278B (zh) | 2020-08-01 |
JP7015822B2 (ja) | 2022-02-15 |
SG10201808940WA (en) | 2018-11-29 |
KR20170002565A (ko) | 2017-01-06 |
AU2015256997B2 (en) | 2020-07-09 |
US20170071902A1 (en) | 2017-03-16 |
JP2015227329A (ja) | 2015-12-17 |
JP6666837B2 (ja) | 2020-03-18 |
JPWO2015170683A1 (ja) | 2017-04-20 |
SG11201609248WA (en) | 2016-12-29 |
CA2948127A1 (en) | 2015-11-12 |
JP2020063283A (ja) | 2020-04-23 |
WO2015170683A1 (ja) | 2015-11-12 |
CN106456597A (zh) | 2017-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7015822B2 (ja) | メトキシフラボンを含むNOX阻害剤及びNFκB阻害剤 | |
TWI682721B (zh) | 黑薑油脂萃取物及其製造方法 | |
KR101694913B1 (ko) | 양파 추출물 또는 이의 분획물을 유효성분으로 함유하는 인지기능 또는 기억능력 개선용 조성물 | |
Alu'datt et al. | Antioxidant and antihypertensive properties of phenolic–protein complexes in extracted protein fractions from Nigella damascena and Nigella arvensis | |
KR101440684B1 (ko) | 클로렐라 유래 항산화 활성을 갖는 펩티드 | |
KR102496450B1 (ko) | 노각나무 추출물을 유효성분으로 포함하는 치매의 예방 또는 치료용 조성물 | |
KR20150034025A (ko) | 항산화 또는 혈당 강하 활성 성분 함량이 증가된 새싹보리 차 | |
KR102058022B1 (ko) | 백산차 추출물의 분획물을 유효성분으로 함유하는 항산화 및 항염증용 조성물 | |
KR20160055748A (ko) | 항산화 또는 혈당 강하 활성 성분 함량이 증가된 새싹보리 차 | |
JP5854592B2 (ja) | 抗酸化剤及び抗炎症剤 | |
KR20160139632A (ko) | 생리활성을 가지는 달래추출물 | |
JP2013060397A (ja) | プロトイソフラボン類の製造方法 | |
KR101866807B1 (ko) | 항알러지 활성을 갖는 감미 단백질 브라제인 변이체 | |
JPWO2005092357A1 (ja) | 抗アレルギー剤および抗炎症剤 | |
Ali et al. | A Concise Review on the Nutritional and Therapeutic Potential of Chia Seeds (Salvia hispanica L.) | |
KR101651106B1 (ko) | 상백피에서 유래된 mac-4-9-1b 비만 치료 또는 예방용 화합물 | |
KR20240111637A (ko) | 생물전환된 당귀 추출물을 유효성분으로 포함하는 인지기능 개선용 조성물 | |
KR101336723B1 (ko) | 삼백초 추출물 또는 이로부터 분리된 화합물을 함유하는 혈관 질환의 치료 또는 예방용 조성물 | |
JP2014217373A (ja) | イワベンケイ属植物エキスの製造方法 | |
KR20190070296A (ko) | 밀양 반시의 미성숙 생감꼭지 추출물을 유효성분으로 포함하는 염증성 질환의 예방, 개선 또는 치료용 조성물 | |
KR100707708B1 (ko) | 삼백초 추출물에서 분리된 sce2520 화합물을함유하는 염증, 알러지성 질환 또는 혈관질환의 예방용건강기능식품조성물 | |
Ajuwon et al. | Improved modulation of the endogenous antioxidant system and inflammatory responses in male wistar rats by rooibos (Aspalathus linearis) and red palm oil (Elaeis guineensis) |